Enliven Therapeutics (ELVN) Return on Invested Capital (2024 - 2025)

Enliven Therapeutics' (ELVN) quarterly Return on Invested Capital came in at 0.0% in Q2 2025, up 15.87% quarter-over-quarter from 0.0% in Q4 2024.

Enliven Therapeutics (ELVN) Return on Invested Capital (2024 - 2025) Analysis & Trends

Enliven Therapeutics has disclosed Return on Invested Capital across 2 years of filings, most recently posting 0.0% for Q2 2025.

Return on Invested Capital for Q2 2025 came in at 0.0%, changed N/A year-over-year; the trailing twelve-month figure through Jun 2025 was 0.0% (changed N/A YoY), and the FY2024 annual result was 0.0%, changed N/A from the prior year.
Return on Invested Capital came in at 0.0% for Q2 2025 at Enliven Therapeutics, up from 0.0% in the prior quarter.
In the past five years, Return on Invested Capital ranged from a high of 0.0% in Q2 2025 to a low of 0.0% in Q4 2024.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	ROIC (Qtr)
1	Alterity Therapeutics	762,369.55 Bn	762,369.51 Bn	-	-
2	Belite Bio	55,096.00 Bn	55,096.00 Bn	-	-
3	Quantum Biopharma	17,755.80 Bn	17,755.79 Bn	-	-
4	Legend Biotech	3,486.00 Bn	3,485.71 Bn	242.10 Mn	0.01%
5	Akari Therapeutics	1,737.42 Bn	1,737.41 Bn	-	-0.01%
6	Evaxion A	1,551.28 Bn	1,551.26 Bn	-	-0.01%
7	Psyence Biomedical	227.32 Bn	227.31 Bn	-	-
8	Vertex Pharmaceuticals	110.84 Bn	103.59 Bn	2.59 Bn	0.00%
9	Abivax	91.71 Bn	91.71 Bn	-	-
10	Enliven Therapeutics	2.32 Bn	2.32 Bn	-	-

Download Data